摘要
目的:探讨不同钙通道阻滞剂治疗原发性高血压的临床疗效及成本-效果比(C/E),为临床合理用药提供理论依据。方法:将150例患者随机分为A、B、C组,每组各50例患者,A组服用硝苯地平控释片,B组服用非洛地平缓释片,C组服用苯磺酸氨氯地平片,治疗8周后进行临床疗效及成本-效果分析。结果:A组患者总有效率90.00%,B组为86.00%,C组为84.00%,三组患者总有效率比较,差异无统计学意义(P>0.05)。A组C/E为3.11,B组C/E为3.93,C组C/E为4.35,A组患者C/E明显低于B组或C组,差异存在统计学意义(P<0.05)。A组C//E为2.80,B组C//E为3.53,C组C//E为3.92,A组患者C//E仍然明显低于B组或C组,差异存在统计学意义(P<0.05)。结论:硝苯地平控释片治疗原发性高血压具有更高的经济学价值,从药物经济学讲,硝苯地平控释片更适合原发性高血压患者长期应用。
Objective： To investigate the clinical effect and the cost-effectiveness ratio（ C /E） of different calcium channel blockers in treatment of primary hypertension,and to provide theoretic foundations for clinical rational administration. Method： 150 patients were randomly divided into group A,group B and group C,and 50 patients in each group. Group A was treated with nifedipine controlled- release tablets,group B treated with felodipine sustaind-release tablets,and the group C treated with amlodipine besylate tablets; In 8 weeks,the clinical therapeutic effects and the cost-effectiveness ratio were analyzed. Result：The total effective rate of the group A,group B and group C were 90.00%,86.00% and 84.00% respectively,and the difference in the total effective rate among the three groups were statistically insignificant（ P＆gt;0.05）. The C / E of the group A,group B and group C were 3.11,3.93 and 4.35 respectively,the C / E of the group A was signfiicantly lower than that of the group B or group C,and the difference was statistically significant（ P＆lt;0.05）. The C / / E of the group A,group B and group C were 2.80,3.53 and 3.92 respectively,the C / / E of the group A was still significantly lower than that of the group B or group C,and the difference was statistically significant（ P＆lt;0.05）. Conclusion： Nifedipine controlled-release tablets in treatment of primary hypertension has higher economic value,and in the aspect of pharmacoeconomics,Nifedipine controlled-release tablets is more suitable for long-term use in primary hypertension patients.
出处
《河北医学》
CAS
2014年第2期242-244,共3页
Hebei Medicine
关键词
药物经济学
成本-效果
原发性高血压
钙通道阻滞剂
Pharmacoeconomics
Cost-effectiveness ratio
Primary hypertension
Calcium channel blockers
